The role of the oral microbiome in smoking-related cardiovascular risk: a review of the literature exploring mechanisms and pathways

J Transl Med. 2022 Dec 12;20(1):584. doi: 10.1186/s12967-022-03785-x.

Abstract

Cardiovascular disease is a leading cause of morbidity and mortality. Oral health is associated with smoking and cardiovascular outcomes, but there are gaps in knowledge of many mechanisms connecting smoking to cardiovascular risk. Therefore, the aim of this review is to synthesize literature on smoking and the oral microbiome, and smoking and cardiovascular risk/disease, respectively. A secondary aim is to identify common associations between the oral microbiome and cardiovascular risk/disease to smoking, respectively, to identify potential shared oral microbiome-associated mechanisms. We identified several oral bacteria across varying studies that were associated with smoking. Atopobium, Gemella, Megasphaera, Mycoplasma, Porphyromonas, Prevotella, Rothia, Treponema, and Veillonella were increased, while Bergeyella, Haemophilus, Lautropia, and Neisseria were decreased in the oral microbiome of smokers versus non-smokers. Several bacteria that were increased in the oral microbiome of smokers were also positively associated with cardiovascular outcomes including Porphyromonas, Prevotella, Treponema, and Veillonella. We review possible mechanisms that may link the oral microbiome to smoking and cardiovascular risk including inflammation, modulation of amino acids and lipids, and nitric oxide modulation. Our hope is this review will inform future research targeting the microbiome and smoking-related cardiovascular disease so possible microbial targets for cardiovascular risk reduction can be identified.

Keywords: Cardiovascular disease; Cardiovascular risk; Genetics; Microbiota; Oral health; Oral microbiome; Smoking.

Publication types

  • Review

MeSH terms

  • Bacteria
  • Cardiovascular Diseases* / etiology
  • Heart Disease Risk Factors
  • Humans
  • RNA, Ribosomal, 16S
  • Risk Factors
  • Smoking / adverse effects

Substances

  • RNA, Ribosomal, 16S